Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents.
Murray
K J
KJ
SmithKline Beecham Pharmaceuticals, Welwyn, Herts, U.K.
England
P J
PJ
D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases / Q000037:antagonists & inhibitors*; D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D001562:Benzimidazoles; D004095:Dihydropyridines / Q000627:therapeutic use; D017335:Enoximone / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D020105:Milrinone; D000078183:Oxindoles; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011724:Pyridazines / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*
D001562:Benzimidazoles; D004095:Dihydropyridines; D007093:Imidazoles; D007527:Isoenzymes; D000078183:Oxindoles; D010726:Phosphodiesterase Inhibitors; D011724:Pyridazines; D011728:Pyridones; D014665:Vasodilator Agents; C064747:ICI 153110; D017335:Enoximone; C053007:adibendan; D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D020105:Milrinone